by John R. Fischer
, Senior Reporter | August 03, 2022
Viz.ai is reducing waiting times and speeding up diagnostic stroke care by integrating its Viz LVO AI technology with Hyperfine’s point-of-care MR scanner, Swoop.
Viz LVO utilizes advanced deep learning to infer time-sensitive information about stroke patients for specialists. Swoop is FDA cleared to provide neuroimaging at patient bedsides, reducing waiting and transport time, as well as adverse events associated with transport.
The companies say the combination will expedite care and MR imaging in both acute and post-acute phases. Delays in stroke care are especially troubling, as they can lead to severe morbidity and mortality.
For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
“Partnering with Hyperfine to enhance the clinical workflow and expedite the clinical team’s access to imaging has the potential to result in better patient outcomes where time is critical in the ER and ICU,” said Jayme Strauss, chief clinical officer at Viz.ai, in a statement.
The two solutions will be deployed together in neuro ICUs where they will be used to further decrease care time, from admission to treatment.
Hyperfine received FDA approval
in 2020 for its system. The solution is 20 times cheaper, 10 times lighter and consumes 35 times less power than fixed conventional MR scanners. It is designed for the nearly 90% of the world that lacks access to MR and has a .064 Tesla magnet, which requires no shielding.
By being able to produce high-quality images at a lower magnetic field strength, clinicians can quickly scan, diagnose and treat patients in various point-of-care clinical settings.
The company also gained FDA approval
for its deep learning, advanced image reconstruction technology which enables Swoop to produce crisp, clear T1, T2 and FLAIR images that are on par in quality with those produced by fixed 1.5T systems.
In addition to stroke, Viz.ai has developed deep learning technology for other neurological conditions. Back in November, it launched two new AI-powered modules
that enable faster clinical decision-making and improved care coordination for pulmonary embolisms and aortic disease.
Following this, it received clearance for Viz ANEURYSM
, an algorithm for detecting suspected cerebral aneurysms to ensure patients get appropriate follow-up care and aneurysm workflow across an entire health system is standardized. Back to HCB News